According to a recent LinkedIn post from Levee Medical, Academic Urology and Urogynecology of Arizona has enrolled its first patient in the ARID II IDE pivotal trial. The site reportedly becomes the 16th location to enroll a patient, underscoring continuing progress in the clinical evaluation of the Voro® Urologic Scaffold.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests that ARID II is focused on assessing both early and long-term continence outcomes following prostate surgery, positioning Voro® as a potential solution in post-prostatectomy care. For investors, steady site activation and patient enrollment in a pivotal IDE study may indicate advancing timelines toward potential regulatory review and eventual commercialization.
If successful, the trial could strengthen Levee Medical’s positioning within the urologic devices segment by addressing a meaningful quality-of-life complication after prostate surgery. Continued enrollment momentum and positive future data readouts would likely be key catalysts for the company’s valuation and its competitiveness versus established continence and reconstructive solutions.